Published in J Clin Oncol on June 15, 2015
All-Cause and Cancer-Specific Mortality Among Patients With Cancer Infected or Not Infected With HIV. J Clin Oncol (2015) 1.09
Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma (2016) 0.80
Maintaining lung health with longstanding HIV. Curr Opin Infect Dis (2016) 0.79
Prevalence and mortality of cancer among HIV-infected inpatients in Beijing, China. BMC Infect Dis (2016) 0.79
Reply to L. Dal Maso et al. J Clin Oncol (2015) 0.79
Factors Associated with Adherence to Routine Screening Mammography in HIV-Infected Women. J Womens Health (Larchmt) (2016) 0.78
Beyond the Pap Smear: Gender-responsive HIV Care for Women. Yale J Biol Med (2016) 0.77
Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Transl Lung Cancer Res (2015) 0.75
Long-term nitrite inhalant exposure and cancer risk in MSM. AIDS (2017) 0.75
Herpes Zoster and Risk of Cancer in the Elderly U.S. Population. Cancer Epidemiol Biomarkers Prev (2015) 0.75
Survival Deficit for HIV-Infected Lymphoma Patients in the National Cancer Database. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Screening for Cancer in Persons Living with HIV Infection. Trends Cancer (2016) 0.75
Lung cancer in persons with HIV. Curr Opin HIV AIDS (2017) 0.75
Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. Surg Oncol Clin N Am (2017) 0.75
Prevalence Of Anal Hpv And Anal Dysplasia In Hiv-Infected Women From Johannesburg, South Africa. J Acquir Immune Defic Syndr (2017) 0.75
Are cancer outcomes worse in the presence of HIV infection? Cancer Epidemiol Biomarkers Prev (2015) 0.75
High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res (2016) 0.75
Outcomes of cervical cancer among HIV-infected and uninfected women treated at the Brazilian National Institute of Cancer (2001-2013). AIDS (2017) 0.75
Racial differences in prostate cancer risk in young HIV-positive and HIV-negative men: a prospective cohort study. Cancer Causes Control (2017) 0.75
Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol (2016) 0.75
Risk Of Colorectal Cancer And Associated Mortality In Hiv: A Systematic Review And Meta-Analysis. J Acquir Immune Defic Syndr (2017) 0.75
Deaths Due to Screenable Cancers Among People Living With HIV Infection, Florida, 2000-2014. Am J Prev Med (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med (2008) 7.71
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998) 6.42
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst (2002) 2.38
Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis (2009) 2.26
Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr (2009) 2.09
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS (2014) 1.86
Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis (2010) 1.78
Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr (2005) 1.71
Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment. J Acquir Immune Defic Syndr (2011) 1.63
Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS (2011) 1.52
Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis (2011) 1.22
Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS (2010) 1.22
Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods. AIDS (2012) 1.19
Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS (2013) 1.19
Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS (2013) 1.16
Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol (1999) 1.10
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica (2007) 1.10
Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol (2014) 1.04
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS (2001) 1.02
Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer (2013) 0.92
Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis (2003) 0.91
Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev (2013) 0.86
HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop (2008) 0.84